Axsome Therapeutics, Inc. (AXSM) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 24 Buy, 1 Hold.
The consensus price target is $222.43 (low: $200.00, high: $260.00), representing an upside of 20.8% from the current price $184.18.
Analysts estimate Earnings Per Share (EPS) of $-5.46 and revenue of $0.39B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.99 vs est $-5.46 (missed -9.8%). 2025: actual $-3.68 vs est $-3.76 (beat +2.1%). Analyst accuracy: 94%.
AXSM Stock — 12-Month Price Forecast
$222.43
▲ +20.77% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Axsome Therapeutics, Inc., the average price target is $222.43, with a high forecast of $260.00, and a low forecast of $200.00.
The average price target represents a +20.77% change from the last price of $184.18.
Highest Price Target
$260.00
Average Price Target
$222.43
Lowest Price Target
$200.00
AXSM Analyst Ratings
Buy
Based on 25 analysts giving stock ratings to Axsome Therapeutics, Inc. in the past 3 months
EPS Estimates — AXSM
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.99
vs Est –$5.46
▼ 8.9% off
2025
Actual –$3.68
vs Est –$3.76
▲ 2.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — AXSM
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.386B
vs Est $0.385B
▲ 0.2% off
2025
Actual $0.638B
vs Est $0.636B
▲ 0.4% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
